摘要
目的:探讨纤溶酶对不同类型冠心病患者白介素-35(IL-35)、白介素-6(IL-6)及转化生长因子-β1(TGF-β1)的影响及其临床意义。方法:将110例患者随机分为纤溶酶组与常规组各55例,采用夹心酶联免疫法(ELISA)测定血浆IL-35、IL-6及TGF-β1水平。比较两组患者治疗前、后IL-35、TGF-β1及IL-6水平变化。结果:治疗后纤组IL-35、TGF-β1升高更明显,IL-6降低更明显(P<0.05),差异有统计学意义;纤组中急性冠脉综合征亚组IL-35、TGF-β1升高较稳定型心绞痛亚组更明显(P<0.05),IL-6降低较稳定型心绞痛亚组更明显(P<0.05)。结论:纤溶酶能升高IL-35、TGF-β1水平,降低IL-6水平,对冠心病疗效确切,且能改善预后。
Objective：Explore the fibrinolytic enzyme in patients with different types of coronary heart disease interleukin-35（IL-35）,interleukin-6（IL-6）and transforming growth factor-β1（TGF-β1）,the influence of and its relationship with the prognosis of patients.Methods：110patients were randomly divided into the fibrinolytic enzyme group and routine group,55 patients with sandwich enzyme-linked immunoassay（ELISA）determination of serum IL-35,IL-6and TGF-β1level.Compare two groups before and after treatment in patients with IL-35,TGF-β1and IL-6level changes.Results：Fiber group after treatment of IL-35,TGF-β1higher more apparent,IL-6reduced more significantly（P〈0.05）,the difference was statistically significant;Fiber group in acute coronary syndrome and IL-35,TGF-β1increases relatively stable angina subgroup more obvious（P〈0.05）,IL-6reduce relatively stable angina subgroup more obvious（P〈0.05）.Conclusion：Fibrinolytic enzyme can increase anti-inflammatory factor（IL-35,TGF-β1）levels,lower levels of inflammatory factors（IL-6）,the curative effect is coronary heart disease,and can significantly improve the prognosis.
出处
《医学理论与实践》
2015年第19期2579-2581,共3页
The Journal of Medical Theory and Practice
